Skip to main content
CADL
NASDAQ Life Sciences

Candel Therapeutics Reports Strong Q1 Results, Extended Cash Runway, and Key Clinical Milestones

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$9
Mkt Cap
$654.828M
52W Low
$4.35
52W High
$9.255
52W Position info
107% above low
Off High info
2.8% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CADL has more than doubled off its 52-week low of $4.35.

Summary

Candel Therapeutics announced its Q1 2026 financial results, highlighting a strong cash position of $194.8 million with a runway into Q1 2028, alongside positive extended survival data for its NSCLC program and a planned BLA submission for prostate cancer in Q4 2026.


Key Events · Product Development and Regulatory · CADL

  • Extended Cash Runway

    Cash and cash equivalents of $194.8 million as of March 31, 2026, are expected to fund operations into Q1 2028, significantly extending the company's financial stability following recent capital raises.

  • Positive NSCLC Clinical Data

    Extended follow-up from the Phase 2a trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) showed 50% of patients surviving beyond 24 months, including those with inadequate response to prior immune checkpoint inhibitors and low PD-L1 status. A pivotal Phase 3 trial is planned for June 2026.

  • Prostate Cancer BLA Submission Plan

    The company plans to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate- to high-risk prostate cancer in Q4 2026, a major step towards commercialization.

  • Commercial Readiness Advancements

    Candel Therapeutics announced a commercial partnership with EVERSANA® to support the potential U.S. launch of aglatimagene in localized prostate cancer, enhancing speed and flexibility for market entry.


Analysis · CADL · Life Sciences

This filing is highly important for Candel Therapeutics as it provides a comprehensive update on its financial health and significant advancements in its clinical pipeline. The company has secured a robust cash position, extending its operational runway into Q1 2028, which is critical for a clinical-stage biotech. Concurrently, it reported compelling extended survival data for its aglatimagene therapy in advanced NSCLC, supporting the initiation of a pivotal Phase 3 trial. Furthermore, the clear plan to submit a Biologics License Application (BLA) for prostate cancer in Q4 2026, coupled with commercialization partnerships, marks a crucial step towards potential market entry. These combined factors significantly de-risk the company's future and provide a strong positive outlook.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CADL was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $654.8M. The 52-week trading range was $4.35 to $9.26. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $6.15 info
Change: +$1.04 (+20%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.15 info
Change: -$2.24 (-27%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.15 info
Change: -$2.24 (-27%) info
Market Cap: $486.365M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $6.15 info
Change: -$4.25 (-41%) info
Market Cap: $486.365M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $6.15 info
Change: -$4.81 (-44%) info
Market Cap: $486.365M info